Equity Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2024

Schedule of Additional Information on Stock Option Grants And Vesting

The following table summarizes additional information on stock option grants and vesting (in thousands):

	2019 Plan
	Three Months Ended March 31, 2024		Three Months Ended March 31, 2023
Total fair value of options vested		1,440		1,465

Stock Based Compensation Expense Included In Condensed Consolidated Statements of Comprehensive Loss

Stock-based compensation expense is included in the Company’s Condensed Consolidated Statements of Comprehensive Loss within the following line items (in thousands):

	Three Months Ended March 31, 2024		Three Months Ended March 31, 2023
Cost of revenues	$	196	$	227
General and administrative		388		443
Research and development		87		76
Sales and marketing		76		87
Total	$	747	$	833

Restricted Stock Units [Member]

Schedule of RSUs Activity Under 2019 Plan

The following table summarizes the Company’s RSU activity for performance based RSUs awarded to employees and for time-based RSUs granted to non-employee directors under the 2019 Plan:

Description	RSUs Outstanding
Outstanding at December 31, 2023		2,429,289
Granted		—
Vested - non-employee director awards		(50,505	)
Forfeited		(1,737	)
Expired		—
Outstanding at March 31, 2024		2,377,047

2019 Plan [Member]

Schedule of Stock Option Activity Under 2019 Plan

The following table summarizes the Company’s stock option activity under the 2019 Plan:

Description	Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (1)
Options outstanding, December 31, 2023		6,529,092		$	6.88		6.9	$	—
Granted		—			—		—		—
Exercised		—			—		—		—
Forfeited		—			—		—		—
Expired		(63,032	)		8.20		—		—
Options outstanding, March 31, 2024		6,466,060		$	6.86		6.9	$	—
Options vested and exercisable, March 31, 2024		5,097,383		$	8.05		6.4	$	—
Options vested and expected to vest, March 31, 2024		6,466,060		$	6.86		6.9	$	—

_______________________________

(1)Aggregate intrinsic value (in thousands) represents the difference between the estimated fair value of the underlying Common Stock and the exercise price of outstanding in-the-money options.